Brevet US8012121 - Method and apparatus for selective material delivery via an intra-renal catheter

Parfrey, et al., Contrast Material-Induced Renal Failure in Patients with Diabetes Mellitus, Renal Insufficiency, or Both, N Engl J Med, 1989, 320:149-153.

Patel, et al., Intravenous Fenoldopam Infusion in Severe Heart Failure, Cardiovasc Drugs Ther 1993; 7:97-101.

Pharmacy and Therapeutics Committe, Fenoldopam Mesylate (Corlopam) Usage Guidelines; Clinical Pharmacy Associaates, Inc. Feb. 2001. http://www.clinpharm.com/client_data/productfiles/ fenoldopam%20usage%20guidelines.pdf Access Nov. 29, 2007. Pierce, “Fenoldopam (Corlopam) DUE”, Pharmacy & Therapeutics Committee, Jan. 2002, http://prodruginfo.com/Formulary/DUE/ fenolddue.pdf, Accessed Sep. 12, 2007.

Postma, C.T. et al.; “Treatment of Renal Artery Stenosis with IntraArterial Stents,” Ned Tijdshr Genneeskd., vol. 142, No. 39, pp. 21322137, Sep. 26, 1998. Abstract Only.

Ramanathan, et al., Ameliorating Contrast-Induced Nephropathy, Journal of Invasive Cardiology, Nov. 2001, Retrieved from the Internet [Online]: www.invasivecardiology.comlfic_20011/jic_ 200111f6.html.

Rebeiz, et al., “Radiocontrast Nephropathy: a Time for Affirmative Action, Jlnvasive Cardiology,” Jan. 2003, vol. 15, No. 1, pp. 23-24. Rihal, et al., “Incidence and Prognostic Importance of Acute Renal Failure After Percutaneous Coronary Intervention,” Circulation, (May 14, 2002),105:2259-2264.

Ritchie, et al., “Use of nonionic or Low Osmolar Contrast Agents in Cardiovascular Procedures,” Retrieved from the Internet [Online] www.acc.org/clinical/position/72543.htm, Jan. 22, 2003.

Robinson, et al., “Congestive Heart Failure: Targeted Drug Therapy and Invasive Interventions”, Retrieved from the Internet [Online] www.speroff.com/articiesITextbook/66_CHF2.htm, printed Sep. 4, 2002.

Rudnick, et al., Nephortoxicity of Ionic and Noionic Contrast Media in 1196 Patients: A Randomized Trial, Kidney International, 1995; 47:254-261.

Schwab, et al., Contrast Nephrotoxicity: A Randomized Controlled Trial of a Nonionic and an Ionic Radiographic Contrast Agent, N Engl J Med, 1989, 320:149-153.

Seiter, H. et al.; “Modified T-Catheter and its use for Transvenous Hypothemic in Situ Perfusion in the Surgical Restoration of the Kidney with Staghorn calculi,” Z. Uro Nephrol., vol. 76, No. 6, pp. 403-406, Jun. 1983. Abstract Only.

Sheifer, “Sex Differences in Coronary Atery Size”, American Heart Journal, 2000; 139(4):649-653.

Shusterman, et al., Fenoldopam, But Not Nitroprusside, Improves Renal Function etc. Am J of Medicine, 95:161-168 (1993).

U.S. Appl. No. 09/165,333—Leschinsky, Boris—“Method and Apparatus for Treating Aneurysms”.

Solomon, et al., Effects of Saline, Mannitol, and Furosemide on Accute Decreases in Renal Function etc., N Engl J Med 1994; vol. 331 No. 21 pp. 1416-1420.

Stevens, et al., A Prospective Randomized Trail of Prevention Measures in Patients at High Risk for Contrast Nephropathy, J Am Coll Cardiol, 1999; 33:403-411.

Strick, et al., Direct Measurement of Renal Medullary Blood Flow in the Dog, Am J . Physiol. 267 (Regulatory Integrative Comp. Physiol. 36): R253-R2259, 1994.

Suehiro, et al ., “Selective Renal Vasodilation and Active Renal Artery Perfusion Improve Renal Function in Dogs with Acute Heart Failure,” The Journal of Pharmacology and Experimental Therapeutics, vol. 298, No. 3 pp. 1154-1160 (2001).

Taliercio, et al., Risks for Renal Dysfunction with Cardiac Angiography, Annals of Internal Medicine, 1986; 104:501-504.

“

Thatipelli et al., CT Angipgraphy of Renal Artery Anantomy for Evaluating Embolic Protection Devices.” Journal of Vascular and Interventional Radiology. 2007; 18(7): 842-846.

Thomas, et al., Glomerrular Filtration Dynamics During Renal Vasodilation etc. Am. J. Physiol. 244:F606-F611 (1983).

Thomas, et al ., Influence of Bradykinin and Papaverine on Renal etc., Renal Physiology, Basel 5:197-205 (1982).

Tumlin et al., “Fenoldopam Mesylate Blocks Reductions in Renal Plasma Flow After Radiocontrast Dye Infusion: A Pilot Trial in the Prevention of Contrast Nephropathy,” The American Heart Journal, 2002; 143:5:894-903.

UIC Collge of Pharmacy, “Is Fenoldopam (Corlopam) Useful for the Prevention Of Contrast Media Associated Nephrotoxicity?”, Retrieved from the Internet [Online] www.uic.edu/pharmacy/services/di/fenoldopam.htm, Jan. 2003.

Umrani et al., Beneficial effects of fenoldopam treatment of renal function in streptozotocin-induced diabetic rats, Clin Exp Hypertens, Apr. 24, 2002 (3): 207-19 Abstract only.

Van Der Zander et al., “Hypertension: Does Brain Natrriuretic Paptide Have a Direct Renal Effect in Human Hypertensives?”, American Heart Association, 2003, 41, 119-123.

Vari, et al., Induction, Prevention and Mechanisms of Contrast Media-Induced Acute Renal Failure, Kidney International, 1988; 33:669-707.

Venkatamaran, “Prevention of acute renal failure,” Crit. Care Clin., 2005, 21(2), 281-289 (abstract).

Walker, H.S. et al.; “Use of a Balloon-Tipped Profusion Catheter for Renal Preservation During Suprarenal Abdominal Aortic Operations,” J. Vasc. Surg., vol. 2, No. 2, pp. 337-339, Mar. 1985. Abstract Only.

Weisberg et al., Risk of radiocontrast nephropathy in patients with and without diabetes mellutus, Kidney International, 1994, 45:259265.

White, C.J. et al.; “Renal Artery Stent Placement: Utility in Lesions Difficult to Treat with Balloon Angioplasty,” Am. Coll. Cardiol., vol. 30, No. 6, pp. 1445-1450, Nov. 15, 1997. Abstract Only.

Williams, D.M. et al.; “Design and Testing of a High-FLo2
Autoperfusion Catheter: An Experimental Study,” J . Vasc. Interv.
Radiol., vol. 3, No. pp. 285-290, May 1992. Abstract Only.
Zacherl, et al. Periarterial Papverine Applications Improves
Intraoperative Kidney Function etc. Journal of Surgical Research
103:268-271 (2002).

Madyoon et al., “Fenoldopam for prevention of contrast-induced renal dysfunction in a high risk angiography population: A historically-controlled case series”, Circulation vol. 104, No. Suppl. 17, XP00908219, Oct. 23, 2001, p. II-185.

Mathur, V.S., “Pathophysiology of radiocontrast nephropathy and use of fenoldopam for its prevention”, Reviews in Cardiovascular Medicine, vol. 2, No. Suppl. 1, 2001, pp. 54-58, XP009098238. Stone, G.W. et al ., “Designand rationale of CONTRAST—a pro spective, randomized, placebo-controlled trial of fendoldopam mesylate for the prevention of radiocontrast nephropathy”, Reviews in Cardiovascular Medicine, vol. 2, No. Suppl. 1, pp. 531-536, XP009098217. Tumlin et al., “A multicenter, double-blind, placebo-controlled trial of fenoldopam meysylate in the prevention of radiocontrast nephropathy in patients with moderate to severe renal insufficiency” Journal ofthe American Society ofNephrology,Vo. 11, Sep. 2000, p. 135A, XP009098223.

Tumlin, J .A. et al., Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy:, American Heart Jouornal, vol. 143, No. 5, May 2002, pp. 894-903, XP002475379.

* cited by examiner